Cole brings over 30 years of successful finance and operations leadership in the diagnostics and life sciences industries.
Currently he is chief financial officer of Genomic Health, a provider of genomic-based diagnostic tests, where he has been influential in steering the company through its initial public offering, growth and profitability, and international expansion.
From 2009 through 2018, Cole served as both chief operating officer and chief financial officer at Genomic Health.
Before joining Genomic Health, he was vice president, finance and business Development for the Endovascular Solutions Group at Guidant Corp., a designer and developer of cardiovascular medical products.
Prior to that, he served as vice president and general manager of the Vascular Surgery Business Unit of Guidant.
Previously he was chief financial officer at Endovascular Technologies, Inc., a publicly traded medical device company acquired by Guidant Corp. in 1997, and chief financial officer at Applied Biosystems, a publicly traded life sciences company until 1994.
In 2017, Cole was recognized for his leadership and named Bay Area CFO of the Year by the San Francisco Business Times.
He has been a member of the Biola University board of Trustees since 2002. He holds a B.S. in business from Biola University and an M.B.A. from San Jose State University.
Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about treatment and follow up care based on the individual molecular signature of the patient's tumor.
The company currently offers tests for patients with cutaneous melanoma (DecisionDx-Melanoma, DecisionDx-CMSeq) and uveal melanoma (DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq), with programmes in development for other underserved cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma.
Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are the trademarks of Castle Biosciences, Inc.
Any other trademarks are the property of their respective owners.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories